Anti–SARS-CoV-2 antibody responses in patients with CLL according to disease status and treatment. (A-B) Response rate and anti–SARS-CoV-2 antibody levels in patients with CLL according to disease status: Treatment naive (n = 58), on-therapy (n = 75), off-therapy in remission (n = 24), and off-therapy in relapse (n = 10). (C) Response rate in patients with CLL treated with BTKi (n = 50) and venetoclax (Ven) ± anti-CD20 antibody (n = 22). NS, not significant.